Group 1 - Hong Kong biopharmaceutical stocks experienced an initial rise on September 8, with major gains observed in several companies [1] - In particular, InnoCare Pharma surged over 13% after being included in the Hang Seng Composite Index [1] - Other notable performers included Junshi Biosciences and WuXi Biologics, which saw increases of over 3% [1]

Group 1 - The stock of EnGeneIC Limited (09606) opened over 4% higher and is currently up 4.63%, trading at 380 HKD with a transaction volume of 7.506 million HKD [1] - EnGeneIC Limited announced that starting from September 8, 2025, its shares will be included in the Hang Seng Composite Index and added to the eligible securities list for the Shanghai-Hong Kong Stock Connect [1] - The inclusion in the Hang Seng Composite Index and the Shanghai-Hong Kong Stock Connect is seen as a recognition of the company's performance and value, potentially expanding its investor base and increasing trading liquidity [1] Group 2 - On September 5, EnGeneIC Limited reported that an independent data monitoring committee (IDMC) evaluated that the DB-1303/BNT323 treatment achieved the primary endpoint of progression-free survival (PFS) in a Phase III clinical trial for HER2-positive unresectable or metastatic breast cancer patients previously treated with trastuzumab and taxanes [1] - The company plans to communicate with the National Medical Products Administration's Drug Evaluation Center regarding the submission of a Biologics License Application (BLA) for DB-1303/BNT323 [2] - DB-1303/BNT323 is a clinical-stage HER2ADCD candidate drug currently undergoing two ongoing registration clinical trials and another potential global registration study [2]

智通财经APP获悉，映恩生物-B(09606)高开逾4%，截至发稿，涨4.63%，报380港元，成交额750.6万港 元。 股份获纳入恒生综合指数及沪港通合资格证券，代表资本市场对公司表现及价值的高度认同，中国内地 合资格投资者从而可以透过上海证券交易所直接投资于香港联合交易所有限公司上市的股份。预期该项 纳入将进一步扩大公司的投资者基础，并有望增加股份的交易流通量。 此外，值得关注的是，9月5日，映恩生物发布公告，经独立数据监察委员会(IDMC)评估，与对照组相 比，DB-1303/BNT323用于既往接受曲妥珠单抗和紫杉烷类治疗的HER2阳性不可切除或转移性乳腺癌患 者的III期临床试验已达到由盲态独立中心审阅(BICR)评估的无进展生存期(PFS)主要研究终点。 公司计划与国家药监局药品评审中心就提交DB-1303/BNT323生物制品上市许可申请(BLA)进行沟通。 DB-1303/BNT323是一款处于临床阶段的HER2 ADCD候选药物，目前正两项进行中的注册性临床试验 及另一项潜在全球注册研究中进行评估。公司的合作伙伴BioNTech SE正在准备于2025年提交的DB- 1303/BNT323 ...

Core Viewpoint - The announcement indicates that Ying'en Bio-B will be included in the Hang Seng Composite Index starting September 8, 2025, reflecting strong recognition of the company's performance and value by the capital market [1] Group 1 - The inclusion in the Hang Seng Composite Index is expected to expand the investor base for the company [1] - The move is anticipated to increase the trading liquidity of the company's shares [1]

Core Viewpoint - The company, Ying'en Biotechnology-B (09606), will be included in the Hang Seng Composite Index and the Hong Kong Stock Connect eligible securities list starting from September 8, 2025, indicating strong market recognition of its performance and value [1] Group 1 - The inclusion in the Hang Seng Composite Index and the Hong Kong Stock Connect will allow qualified investors in mainland China to directly invest in the company's shares listed on the Hong Kong Stock Exchange [1] - This inclusion is expected to further expand the company's investor base and potentially increase the trading liquidity of its shares [1]

映恩生物-B(09606)发布公告，自2025年9月8日起，公司股份将(i)获恒生指数有限公司纳入恒生综合指 数成份股及(ii)被调入沪港通下港股通标的名单。 股份获纳入恒生综合指数及沪港通合资格证券，代表资本市场对公司表现及价值的高度认同，中国内地 合资格投资者从而可以透过上海证券交易所直接投资于香港联合交易所有限公司上市的股份。预期该项 纳入将进一步扩大公司的投资者基础，并有望增加股份的交易流通量。 ...

Core Viewpoint - The announcement indicates that Ying'en Biotechnology-B (09606.HK) will be included in the Hang Seng Composite Index and the Stock Connect program starting September 8, 2025, reflecting strong market recognition of the company's performance and value [1] Group 1 - The inclusion in the Hang Seng Composite Index and Stock Connect signifies a significant endorsement from the capital market [1] - This move allows qualified investors from mainland China to directly invest in the company's shares listed on the Hong Kong Stock Exchange through the Shanghai Stock Exchange [1] - The anticipated inclusion is expected to broaden the company's investor base and potentially increase the trading liquidity of its shares [1]

Duality Biotherapeutics, Inc. 映恩生物 （根據開曼群島法律註冊成立的有限公司） 香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其準確性 或完整性亦不發表任何聲明，並明確表示概不就因本公告全部或任何部分內容而產生或因依賴 該等內容引致的任何損失承擔任何責任。 自願性公告 本公告由映恩生物（「本公司」）作出，旨在向其股東及潛在投資者提供有關本公司 最新發展動態的資料。 香港，2025年9月7日 （股份代號：9606） 納入恒生綜合指數成份股 及獲調入港股通證券名單 本公司董事會（「董事會」）欣然宣佈，自2025年9月8日起，本公司股份（「股份」） 將(i)獲恒生指數有限公司納入恒生綜合指數成份股及(ii)被調入滬港通下港股通標 的名單。 股份獲納入恒生綜合指數及滬港通合資格證券，代表資本市場對本公司表現及價 值的高度認同，中國內地合資格投資者從而可以透過上海證券交易所直接投資於 香港聯合交易所有限公司上市的股份。預期該項納入將進一步擴大本公司的投資 者基礎，並有望增加股份的交易流通量。 承董事會命 映恩生物 董事會主席、執行董事兼首席執行官 朱忠遠博士 於 ...

Core Insights - BioNTech has achieved a successful mid-stage analysis for an experimental drug in collaboration with InnoCare Pharma, showing better results in breast cancer treatment compared to Roche's established drug Kadcyla [1] - The trial involved 228 patients in China who had metastatic cancer and were previously treated with chemotherapy and trastuzumab [1] - This success marks BioNTech's first significant outcome in a late-stage trial for its cancer compounds, which are crucial for the company's future growth [1] Company Developments - BioNTech's collaboration with InnoCare Pharma has resulted in its first successful outcome in a late-stage trial, indicating potential for regulatory approval [1] - The company has previously generated billions in revenue through its COVID-19 vaccine partnership with Pfizer [1] - InnoCare Pharma focuses on developing antibody-drug conjugates (ADCs) and has established partnerships with other companies like GlaxoSmithKline and Avenzo Therapeutics [1] Market Reaction - Following the news of the successful trial, InnoCare Pharma's stock has surged over 280% since its listing in Hong Kong in April [2] - BioNTech's stock rose nearly 7% in pre-market trading following the announcement [2]

映恩生物-B(09606)发布公告，经独立数据监察委员会(IDMC)评估，与对照组相比，DB-1303/BNT323用 于既往接受曲妥珠单抗和紫杉烷类治疗的HER2阳性不可切除或转移性乳腺癌患者的III期临床试验(该试 验)已达到由盲态独立中心审阅(BICR)评估的无进展生存期(PFS)主要研究终点。 根据这项中期分析结果，本公司计划与中国国家药品监督管理局(国家药监局)药品审评中心(药审中心) 就提交DB-1303/BNT323生物制品上市许可申请(BLA)进行沟通。 该试验是一项在中国进行的随机、对照、开放标签、多中心的III期临床试验，旨在评估DB-1303相较于 T-DM1在既往接受曲妥珠单抗和紫杉烷类治疗的HER2阳性不可切除或转移性乳腺癌患者中的疗效和安 全性。 ...